Novartis Oncology Auditor Salaries in Wilmington, DE | Comparably
At Novartis Oncology, we are passionate about the discovery and development of innovative medicines. read more
EMPLOYEE
PARTICIPANTS
14
TOTAL
RATINGS
161

Novartis Oncology Auditor Salaries in Wilmington, DE

The average Novartis Oncology Auditor in Wilmington, DE earns an estimated $73,545 annually. Novartis Oncology's Auditor compensation is $10,850 less than the US average for a Auditor.

In Wilmington, DE, The Finance Department at Novartis Oncology earns $16,348 more on average than the Admin Department.

Last updated 3 years ago.

$27k
$41k
$57k
$73k
$282k
$340k
$450k
$73,545
Average Compensation
$73,545
avg. base

Auditor Salaries at Novartis Oncology

In Wilmington, DE, Auditors earn $2,537 more than Financial Analysts, and $16,735 less than Senior Accountants.

Accounting Manager
$119k*
Business Analyst
$94k*
Senior Accountant
$90k*
Financial Analyst
$71k*
Accountant
$69k*
* estimated salary

Compensation at Novartis Oncology by Department

In Wilmington, DE, The Finance Department averages $16,348 more than the Admin Department, and $12,531 less than the IT Department

IT
$95,606 Avg. total comp.
+$13k
Finance
$83,075 Avg. total comp.
Admin
$66,727 Avg. total comp.
-$16k

Auditor Compensation by Gender (All Companies)

The average female Auditor at companies similar size to Novartis Oncology reported making $88,019, while the average male Auditor at similar sized companies reported making $86,640.

Auditor Compensation by Ethnicity (All Companies)

The average Hispanic or Latino Auditor at companies similar size to Novartis Oncology reported making $111,857, while the average African American/Black Auditor at similar sized companies reported making $67,169.

How Auditors at Novartis Oncology Rate Their Compensation

The majority of Auditors at Novartis Oncology believe they're not compensated fairly. 100% of Auditors at Novartis Oncology say they receive annual bonuses, and the vast majority (83%) are satisfied with their benefits. See more compensation ratings at Novartis Oncology

×
Rate your company